Abstract
BackgroundPapillary renal cell carcinoma (pRCC) ranks second in renal cell carcinoma and the prognosis of pRCC remains poor. Here, we aimed to screen and identify a novel prognostic cancer-related lncRNA signature in pRCC.MethodsThe RNA-seq profile and clinical feature of pRCC cases were downloaded from TCGA database. Significant cancer-related lncRNAs were obtained from the Immlnc database. Differentially expressed cancer-related lncRNAs (DECRLs) in pRCC were screened for further analysis. Cox regression report was implemented to identify prognostic cancer-related lncRNAs and establish a prognostic risk model, and ROC curve analysis was used to evaluate its precision. The correlation between RP11-63A11.1 and clinical characteristics was further analyzed. Finally, the expression level and role of RP11-63A11.1 were studied in vitro.ResultsA total of 367 DECRLs were finally screened and 26 prognostic cancer-related lncRNAs were identified. Among them, ten lncRNAs (RP11-573D15.8, LINC01317, RNF144A-AS1, TFAP2A-AS1, LINC00702, GAS6-AS1, RP11-400K9.4, LUCAT1, RP11-63A11.1, and RP11-156L14.1) were independently associated with prognosis of pRCC. These ten lncRNAs were incorporated into a prognostic risk model. In accordance with the median value of the riskscore, pRCC cases were separated into high and low risk groups. Survival analysis indicated that there was a significant difference on overall survival (OS) rate between the two groups. The area under curve (AUC) in different years indicated that the model was of high efficiency in prognosis prediction. RP11-63A11.1 was mainly expressed in renal tissues and it correlated with the tumor stage, T, M, N classifications, OS, PFS, and DSS of pRCC patients. Consistent with the expression in pRCC tissue samples, RP11-63A11.1 was also down-regulated in pRCC cells. More importantly, up-regulation of RP11-63A11.1 attenuated cell survival and induced apoptosis.ConclusionsTen cancer-related lncRNAs were incorporated into a powerful model for prognosis evaluation. RP11-63A11.1 functioned as a cancer suppressor in pRCC and it might be a potential therapeutic target for treating pRCC.
Highlights
Papillary renal cell carcinoma ranks second in renal cell carcinoma and the prognosis of pRCC remains poor
The differentially expressed cancer-related long non-coding RNAs (lncRNAs) (DECRLs) were removed if their expression values were equal to 0 in more than 135 samples
The cancer‐related lncRNA signature was an independent factor in prognosis prediction We further evaluated whether the identified cancerrelated lncRNA signature was an independent factor for prognosis prediction in pRCC
Summary
Papillary renal cell carcinoma (pRCC) ranks second in renal cell carcinoma and the prognosis of pRCC remains poor. Renal cell carcinoma (RCC) is a main human malignancy threatening people’s health globally. It is mainly divided into three catalogues, including clear cell RCC (ccRCC), In recent decades, long non-coding RNAs (lncRNAs) are reported to be aberrantly expressed in many. Chen et al Cancer Cell Int (2021) 21:545 malignancies and involved in the oncogenesis and progression of human cancers, and they have great potential to serve as biomarkers for cancer diagnosis and targets for cancer treatment [5]. What’s more, a series of lncRNAs have been identified as cancer-related lncRNAs [10,11,12,13]. LncRNAs, especially cancer-related lncRNAs are promising biomolecules in human cancers
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
